Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma
In patients with metastatic renal cell carcinoma, treatment with sunitinib in the first-line setting was associated with improved overall survival when compared with treatment with pazopanib, according to research published by Naveen S. Basappa, MD, of the University of Alberta, Edmonton, and colleagues, in the Canadian Urological Association Journal.
As first-line treatment for metastatic renal cell carcinoma, clinical trial data have shown pazopanib to be noninferior to sunitinib in terms of overall survival. The team of Canadian researchers sought to evaluate outcomes in patients who had been treated with sunitinib or pazopanib in the real-world setting.
Data were collected using the prospective Canadian Kidney Cancer Information System database from January 2011 to November 2015. They identified a total of 670 patients: 577 treated with sunitinib and 93 treated with pazopanib.
Patients treated with sunitinib had improved overall survival compared with pazopanib (median, 31.7 vs. 20.6 months). Time to treatment failure was also numerically, though not statistically, improved with sunitinib (median, 11.0 vs. 8.4 months).
“Patient selection factors and the contemporary practice of individualized dosing with sunitinib may contribute to these real-world outcomes and warrant further investigation,” the investigators concluded.